

Marc Van den Eynde

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10110444/publications.pdf>

Version: 2024-02-01

28
papers

2,728
citations

623734

14
h-index

580821

25
g-index

29
all docs

29
docs citations

29
times ranked

5054
citing authors

#	ARTICLE	IF	CITATIONS
1	International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. <i>Lancet, The</i> , 2018, 391, 2128-2139.	13.7	1,487
2	Evolution of Metastases in Space and Time under Immune Selection. <i>Cell</i> , 2018, 175, 751-765.e16.	28.9	322
3	The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients. <i>Cancer Cell</i> , 2018, 34, 1012-1026.e3.	16.8	209
4	Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival. <i>Journal of the National Cancer Institute</i> , 2018, 110, 97-108.	6.3	199
5	Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 3638-3651.	1.6	130
6	A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy. <i>Clinical Cancer Research</i> , 2020, 26, 5198-5207.	7.0	66
7	Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab. <i>Hpb</i> , 2013, 15, 858-864.	0.3	50
8	Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer. , 2020, 8, e000272.		43
9	Surgical Treatment of Colorectal Cancer with Peritoneal and Liver Metastases Using Combined Liver and Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Report from a Single-Centre Experience. <i>Annals of Surgical Oncology</i> , 2016, 23, 666-673.	1.5	31
10	Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine. <i>Cancers</i> , 2022, 14, 2241.	3.7	26
11	Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT) Tj ETQq1 1 0.4784314 rgBT /Ov	4.7	14
12	Prognostic assessment of resected colorectal liver metastases integrating pathological features, <sc><i>RAS</i></sc> mutation and Immunoscore. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 27-41.	3.0	24
13	Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1792-1801.	6.4	17
14	The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0138341.	2.5	16
15	Endoscopic mucosal or submucosal resection of early neoplasia in Barrett's esophagus after antireflux surgery. <i>Gastrointestinal Endoscopy</i> , 2010, 72, 855-861.	1.0	15
16	CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial. <i>BMC Cancer</i> , 2019, 19, 304.	2.6	13
17	Multiverse of immune microenvironment in metastatic colorectal cancer. <i>Oncolmmunology</i> , 2020, 9, 1824316.	4.6	9
18	Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur). <i>Acta Clinica Belgica</i> , 2021, , 1-7.	1.2	9

#	ARTICLE	IF	CITATIONS
19	Prediction of tumor response and patient outcome after radioembolization of hepatocellular carcinoma using 90Y-PET-computed tomography dosimetry. <i>Nuclear Medicine Communications</i> , 2021, 42, 747-754.	1.1	9
20	The absence of benefit of perioperative chemotherapy in initially resectable peritoneal metastases of colorectal cancer origin treated with complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A retrospective analysis. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1661-1667.	1.0	8
21	SoMore trial: Early metabolic response assessment of a sorafenib (SOR) and capecitabine (CAP) combination in chemorefractory metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 524-524.	1.6	5
22	Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab. <i>Drugs in R and D</i> , 2019, 19, 267-275.	2.2	4
23	Immunity to live: an immunopathoscore using the consensus Immunoscore to best define the risk of recurrence and death in stage IV metastatic patients. <i>Oncolimmunology</i> , 2020, 9, 1826133.	4.6	4
24	Metastasis immune-based scores predict patient survival. <i>Oncolimmunology</i> , 2020, 9, 1806000.	4.6	4
25	Preoperative (preop) chemosensitivity testing as predictor of treatment benefit in adjuvant stage III colon cancer (CC): Interim analysis of the PEPITA study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 385-385.	1.6	1
26	Randomized Phase 2 Study Comparing Pathological Responses of Resected Colorectal Cancer Metastases after Bevacizumab with mFOLFOX6 or FOLFIRI (BEV-ONCO Trial). <i>Cancers</i> , 2022, 14, 1183.	3.7	1
27	Fortnightly or fractionated weekly docetaxel+ cisplatin+ 5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study. <i>Cancer Medicine</i> , 2021, 10, 4366-4374.	2.8	0
28	Phase II trial of preoperative radiotherapy (RT) and panitumumab (PAN) in KRAS wild type (wt) rectal cancer (RC).. <i>Journal of Clinical Oncology</i> , 2012, 30, e14060-e14060.	1.6	0